IsoRay Appoints Chief Executive Officer

IsoRay Inc., a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, announced that Lori Woods has been named CEO.   
 
Board Chairman Mick McCormick said, “Lori Woods has proven to be exceptionally well-qualified to lead IsoRay forward into an exciting new chapter of sustained growth and innovation. Lori’s prior successes in the roles she held across company functions, her deep experience in the industry and her thoughtful and knowledgeable approach to the market will be invaluable as we evolve our product offerings and expand our market opportunities. After six months of rigorous evaluation and extensive interviews with Lori and the management team as well as our examination of the company’s progress over the past six months, we are confident that Lori is the right choice to move the company forward.”

Woods returns to IsoRay bringing more than 30 years’ experience in the medical device technology and healthcare services industries. Woods first joined IsoRay as a vice president in July 2006. Her prior positions with the company also include roles as acting chief operating officer (COO) starting in February 2008 and her subsequent appointment as COO from February 2009 through January 2010. Immediately prior to her appointment as interim CEO in June 2018, Woods was a consultant to the company.

Woods’ appointment as CEO is effective immediately.
 
IsoRay Inc., through its subsidiary, IsoRay Medical Inc. is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. The company is based in Richland, Wash.